Cinolazepam Stats & Data
N#CCCN1C(=O)C(O)N=C(c2ccccc2F)c2cc(Cl)ccc12XAXMYHMKTCNRRZ-UHFFFAOYSA-NPharmacology
DrugBankDescription
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Mechanism of Action
Cinolazepam binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Pharmacodynamics
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Absorption
Bioavailability following oral administration is 90-100%.
Toxicity
The onset of impairment of consciousness is relatively rapid in benzodiazepine poisoning. Onset is more rapid following larger doses and with agents of shorter duration of action. The most common and initial symptom is somnolence. This may progress to coma Grade I or Grade II following very large ingestions.
Indication
For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
Effect Profile
CuratedStrong euphoria and anxiolysis with mild sedation and cognitive impairment